Binge Eating Disorder — SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Citation(s)
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder